<原著論文>尿路上皮癌患者の尿中剥離細胞における17番染色体数およびHER-2遺伝子異常の臨床的意義

概要

論文の詳細を見る
This study was conducted to elucidate the clinical significance of thealterations of HER-2 gene (HER-2) and chromosome 17 centromere in urine-exfoliatedcells by fluorescence in situ hybridization (FISH) in 103 patients with urothelialtransitional cell carcinoma. The additional increase of HER-2 (AI-HER2), gain ofchromosome 17 (G-17), and AI-HER2 with G-17 (AI-HER2+G-17) in the urine-exfoliatedcells were examined by FISH using DNA probes for HER-2 and chromosome17 centromere. AI-HER2, AI-HER2+G-17, and G-17 were found in 13 (12.6%), 10(9.7%), and 36 (35.0%) patients, respectively. The positive rate of the FISH (AIHER2,AI-HER2+G-17, or G-17) was higher than that of cytology in total cases (57.3%vs. 45.6%, P<0.001), in low-stage (pTa-I) tumors (44.3% vs. 27.9%, P= 0.003), and incases without CIS (42.0% vs. 31.9%, p<O.OOI). AI-HER2 was significantly more frequentin tumors with two or more recurrences (25.9% vs. 7.9%, P=0.037). AI-HER2+G-17 was more frequent in cases with primary CIS than without CIS (26.7% vs. 3.0%,p =0.008). Numerical alterations of HER-2 and the chromosome 17 centromere in theurine-exfoliated cells detected by FISH may reflect the malignant potential of urothelialcarcinoma and could be used as markers for the recurrence and the presence of primaryCIS.
秋田大学の論文